Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Artificial Intelligence-Enhanced Longitudinal Cohort Study to Optimize Revascularization Decisions in Patients With Coronary Artery Disease and Immune Thrombocytopenia (The ITP-CAD AI-REVASC Study)

NCT07426107 is registered in ClinicalTrials.gov with Xiao Hui Zhang as lead sponsor.

NCT NCT07426107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07426107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Artificial Intelligence-Enhanced Longitudinal Cohort Study to Optimize Revascularization Decisions in Patients With Coronary Artery Disease and Immune Thrombocytopenia (The ITP-CAD AI-REVASC Study)
Lead sponsor
Xiao Hui Zhang
Phase
Observational
Overall status
Not yet recruiting
Start date
February 25, 2026
Completion date
February 25, 2029
Enrollment
600 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, immune thrombocytopenic purpura